General information
Tools for COVID-19 annotation
Annotation widget
- We have imported the annotation widget, that we use for systematic review annotation, in to the CRS Web
- If you cannot access the CRS Web please contact Deirdre Beecher
COVID-19Register in CRS Web
- The register will be listed with any other registers that you access via the CRS Web
- Search and layout is identical to that in other CRS registers
Annotation status & fields
- Additional fields have been added to the CRS records to assist us in our workflow
Expand | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
|
- Three annotation status are available
Expand | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
|
Basic steps
- Search the COVID-19 Register for studies
- Login to CRS Web
- Select COVID-19 Register (only applies to those who use multiple registers)
- Make sure you have ticked IN REGISTER (you do not want to search beyond this)
- Search for study using the title or study ID
- Open annotation widget within the record
- Annotate and Complete!
Annotation detail required
Population/Condition | Intervention | Comparator | Outcomes |
---|---|---|---|
|
|
|
|
- dosage, schedule etc not required unless is the comparison
Terms not already in vocabulary
- our Vocabulary browser is available HERE
Info | ||
---|---|---|
| ||
In some cases you will not be able to complete a full annotation. We ask that you:
|
HTML |
---|
<a href="#com-atlassian-confluence">Back to Top</a> |
Priority studies to annotate
Info | ||
---|---|---|
| ||
These may change over time depending on topics to be coved in rapid reviews. |
For both priority 1 and 2 please search for
- studies with results (journal article or preprint article) then
- trial registry records
The reference type can be selected on our Study Register
Priority 1
Limit search to
- Study Reference Type: Journal Article/Preprint Article
- Intervention Assignment: Randomised
Any of the following interventions:
- Hand cleaning with ash
- Convalescent plasma, convalescent serum or convalescent hyperimmune immunoglobulin
- Any intervention in which a core component involves the use of the internet to facilitate video calls or video conferencing through computers, smartphones or tablets
- chloroquine, remdesivir, or corticosteroids
Priority 2
- Study Reference Type: Journal Article/Preprint Article
- Intervention Assignment: Non-randomised or Unclear or Quasi-randomised
Any of the following interventions:
- Hand cleaning with ash
- Convalescent plasma, convalescent serum or convalescent hyperimmune immunoglobulin
- Any intervention in which a core component involves the use of the internet to facilitate video calls or video conferencing through computers, smartphones or tablets
- chloroquine, remdesivir, or corticosteroids
Searching to identify priority trials
- Search on https://covid-19.cochrane.org/
- Restrict to Study Type: Interventional
- For the specific interventions:
- Text search for ash*
- Text search for convalescent
- etc.
Topics/vocabulary
- Before you start annotating please check that the Cochrane Linked Data Vocabulary to determine whether or not terms are available
- If not available, place your request in the covid19-study-annotation channel in Slack and alert Anna last
Vocabulary notes
Age
A number of studies will state in their inclusion criteria Aged 18 years or older. Please annotate as:
Young Adult 19-24 years or Adult 19-44 years or Middle Aged 45-64 years or Aged 65-79 years or Aged 80 and over 80+ years |
Drug combinations
Use the individual drugs with AND
At Risk Of
In some studies the inclusion criteria population is 'At risk of ...' - in this case we do not annotate the condition in the Population but only as an Outcome
Table of misc. terms and their categories
Table Filter | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Time to ...
Time to Clinical Improvement | https://data.cochrane.org/concepts/1ZAQeEkwo0cpmW |
Time to Clinical Recovery | https://data.cochrane.org/concepts/OW7PMP5pAaCBgR |
Time to defervescence | https://data.cochrane.org/concepts/6nyXkn9P8DIPG3 |
Time to cough | Cough |
Time to Dyspnea | Dyspnea |
Time till the virus nucleic acid test goes negative/ Transition time of novel coronavirus nucleic acid" |
Outcome annotation examples
Study | Outcome | Outcome detail | Annotation |
---|---|---|---|
NCT04278963 | respiratory progression | Defined as: SPO2≤ 93% on room air or PaO2/FiO2≤ 300mmHg and requirement for supplemental oxygen or more advanced ventilator support | Hypoxia AND (Oxygen therapy OR mechanical ventilation) - all in the same outcome group |